Mutational analysis of the p27kip1 gene in hepatocellular carcinoma

被引:19
作者
Chen, TC
Ng, KF
Lien, JM
Jeng, LB
Chen, MF
Hsieh, LL [1 ]
机构
[1] Chang Gung Univ, Dept Publ Hlth, Tao Yuan, Taiwan
[2] Chang Gung Univ, Dept Pathol, Tao Yuan, Taiwan
[3] Chang Gung Mem Hosp, Tao Yuan, Taiwan
[4] Chang Gung Univ, Dept Internal Med, Div Hepatogastroenterol, Tao Yuan, Taiwan
[5] Chang Gung Univ, Dept Surg, Tao Yuan, Taiwan
关键词
hepatocellular carcinoma; p27; Kip1; single strand conformation polymorphism;
D O I
10.1016/S0304-3835(00)00366-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p27(Kip1) is an inhibitor of cyclin-dependent kinase. It has been reported that reduced p27(Kip1) expression is present in human hepatocellular carcinoma. To determine the role of p27(Kip1) in hepatocarcinogenesis, 46 cases with hepatocellular carcinomas were studied. p27(Kip1) mutation was first screened by single strand conformation polymorphism. and direct DNA sequencing was then performed on those casts with mobility shifts. Two polymorphism sites were found. One is a previously described polymorphism at codon 109 (GTC --> GGC) which was found in two cases. The second polymorphism was identified at codon 55 (GCG --> GCA) in six of the 46 cases. However. the polymorphism at codon 55 was also present in seven of 93 healthy controls (7.5%). indicating that it is not associated with a predisposition for development of hepatocellular carcinoma (Fishers exact test, P > 0.05). These results show that p27(Kip1) mutation is not a frequent event in human hepatocellular carcinoma. and suggest that it may be inactivated predominantly by transcriptional and/or posttranscriptional regulation rather than genomic aberrations. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:169 / 173
页数:5
相关论文
共 26 条
[1]  
Anthony P. P., 1994, P635
[2]   SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].
BRESSAC, B ;
KEW, M ;
WANDS, J ;
OZTURK, M .
NATURE, 1991, 350 (6317) :429-431
[3]   Cell cycle and cancer: Critical events at the G1 restriction point [J].
DelSal, G ;
Loda, M ;
Pagano, M .
CRITICAL REVIEWS IN ONCOGENESIS, 1996, 7 (1-2) :127-142
[4]  
DEP HLTH, 1998, HLTH VIT STAT, P10
[5]   MUTATIONAL HOTSPOT IN THE P53 GENE IN HUMAN HEPATOCELLULAR CARCINOMAS [J].
HSU, IC ;
METCALF, RA ;
SUN, T ;
WELSH, JA ;
WANG, NJ ;
HARRIS, CC .
NATURE, 1991, 350 (6317) :427-428
[6]   Inactivation of p16(INK4) in hepatocellular carcinoma [J].
Hui, AM ;
Sakamoto, M ;
Kanai, Y ;
Ino, Y ;
Gotoh, M ;
Yokota, J ;
Hirohashi, S .
HEPATOLOGY, 1996, 24 (03) :575-579
[7]   Reduced p27Kip1 expression in hepatocellular carcinomas [J].
Hui, AM ;
Sun, L ;
Kanai, Y ;
Sakamoto, M ;
Hirohashi, S .
CANCER LETTERS, 1998, 132 (1-2) :67-73
[8]   Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas [J].
Hui, AM ;
Kanai, Y ;
Sakamoto, M ;
Tsuda, H ;
Hirohashi, S .
HEPATOLOGY, 1997, 25 (03) :575-579
[9]   CYCLINS AND CANCER .2. CYCLIN-D AND CDK INHIBITORS COME OF AGE [J].
HUNTER, T ;
PINES, J .
CELL, 1994, 79 (04) :573-582
[10]   Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence [J].
Ito, Y ;
Matsuura, N ;
Sakon, M ;
Miyoshi, E ;
Noda, K ;
Takeda, T ;
Umeshita, K ;
Nagano, H ;
Nakamori, S ;
Dono, K ;
Tsujimoto, M ;
Nakahara, M ;
Nakao, K ;
Taniguchi, N ;
Monden, M .
HEPATOLOGY, 1999, 30 (01) :90-99